The Securities and Exchange Commission (SEC) has reportedly launched an investigation into Cassava Sciences in response to allegations made against the clinical-stage biopharmaceutical company by a law firm representing anonymous short sellers.
Cassava disclosed in a regulatory filing on Nov. 15 that “certain government agencies have asked us to provide them with corporate information and documents” and that it is cooperating with these requests.
